Douglas S. Bush, MD

Clinical Focus

• Down Syndrome
• Pulmonary Hypertension

• Down Syndrome
• Pulmonary Hypertension

Research

Locations

Faculty Practice Associates

Pediatric Pulmonology, 5 East 98th Street, 10th Floor, New York, NY, 10029

212-241-7788

Pediatric Pulmonary Hypertension Clinic

Children’s Heart Center, 1468 Madison Avenue, Annenberg, 3rd Floor, New York, NY, 10029

844-733-7692

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:7

Article:11

Review Article:4

Comment/Debate:1

Letter:3

Chapter:1

Recent Artifacts

• Impact of COVID-19 on pediatric asthma-related healthcare utilization in New York City: a community-based study
• Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c⁺ B cells
• Cardiovascular complications of sleep disordered breathing in the population with Down syndrome
• Associations between early-life exposure to PM_2.5and reductions in childhood lung function in two North American longitudinal pregnancy cohort studies
• Prominent intrapulmonary shunt vessels and altered lung development in infants with sudden unexplained infant death
• Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome
• Microvascular Shunts in COVID-19 Pneumonia
• Prenatal lead exposure and childhood lung function: Influence of maternal cortisol and child sex
• Pulmonary Hypertension in the Population with Down Syndrome
• Atypical Inflammatory Syndrome Triggered by SARS-CoV-2 in Infants with Down Syndrome

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Bush did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.